Altogether, our results demonstrate that low expression of NKX2‐1 fosters tumor growth, and targeting the CXCLs/CXCR2 axis with SB225002 mitigates the tumor growth induced by NKX2‐1 downregulation. Here, CXCR2 is linked to neoplasm.